| Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. | |
| | |
MedLine Citation:
|
PMID: 18827493 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The p160 nuclear receptor coactivator, AIB1 (amplified in breast cancer 1), is frequently overexpressed in human breast cancer and has been shown to be associated with tamoxifen resistance. The present study aimed to investigate the role of AIB1 in tamoxifen resistance of breast cancer cells. METHODS: We reconstructed the RNA interference expression vector, pGenesil-1-U6, specially targeting AIB1 mRNA, and it was stably transfected into the human breast cancer cell line BT474. Cell proliferation and cell cycle distribution were assessed in the cells transfected with scramble control shRNA (BT474/shControl) and AIB1 shRNA (BT474/shAIB1) to explore the possible functions of AIB1 in breast cancer progression. The expression of AIB1, ERalpha, HER2 and pS2 was analyzed in the presence of 17beta-estradiol or 4-hydroxytamoxifen (Tam) by Western blot analysis. RESULTS: Compared with the parental BT474 and the BT474/shControl cells, the levels of AIB1 mRNA and protein were significantly reduced in BT474/shAIB1 cells. A knockdown of AIB1 levels restored the inhibitory effect of tamoxifen on cell proliferation. CONCLUSIONS: Tam behaves like an estrogen agonist in ER-positive breast cancer cells that express high levels of AIB1 and HER2, resulting in de novo resistance. Knockdown of AIB1 can eliminate this cross talk and restore the antitumor effects of tamoxifen. |
| | |
Authors:
|
Qingbo Su; Sanyuan Hu; Haidong Gao; Rong Ma; Qifeng Yang; Zhenhua Pan; Tiantian Wang; Feng Li |
Related Documents
:
|
11205223 - Ectopic lobular breast cancer of the vulva. 14965173 - Clinical assessment of 324 breast cancer cases in two centers between the years of 1992... 7959183 - Dysplasia and aneuploidy as markers of malignant degeneration in barrett's oesophagus. ... |
Publication Detail:
|
Type: Journal Article Date: 2008-10-01 |
Journal Detail:
|
Title: Oncology Volume: 75 ISSN: 1423-0232 ISO Abbreviation: Oncology Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-10-30 Completed Date: 2008-11-18 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 0135054 Medline TA: Oncology Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 159-68 Citation Subset: IM |
Copyright Information:
|
Copyright 2008 S. Karger AG, Basel. |
Affiliation:
|
Department of General Surgery, Qilu Hospital, Shandong University, Jinan, PR China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Base Sequence Blotting, Western Breast Neoplasms / drug therapy*, metabolism*, pathology Cell Cycle / drug effects Cell Proliferation / drug effects Drug Resistance, Neoplasm* Estradiol / pharmacology Estradiol Antagonists / therapeutic use* Estrogen Receptor alpha / metabolism* Histone Acetyltransferases / physiology* Humans Molecular Sequence Data Nuclear Receptor Coactivator 3 Presenilin-2 / genetics, metabolism RNA, Messenger / genetics, metabolism RNA, Small Interfering / pharmacology Reverse Transcriptase Polymerase Chain Reaction Tamoxifen / analogs & derivatives*, therapeutic use Trans-Activators / physiology* Transcription, Genetic Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/Estradiol Antagonists; 0/Estrogen Receptor alpha; 0/PSEN2 protein, human; 0/Presenilin-2; 0/RNA, Messenger; 0/RNA, Small Interfering; 0/Trans-Activators; 0/hydroxytamoxifen; 10540-29-1/Tamoxifen; 50-28-2/Estradiol; EC 2.3.1.48/Histone Acetyltransferases; EC 2.3.1.48/NCOA3 protein, human; EC 2.3.1.48/Nuclear Receptor Coactivator 3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and sta...
Next Document: Gender differences in treatment outcomes among patients with non-small cell lung cancer given a comb...